(Glioma) Oncolytic Virus Therapy for Cancer Treatment Now Available in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 8, 2021
- Reading time: 1 minute
On November 1, 2021, Daiichi Sankyo announced the commercial launch in Japan of teserpaturev, an oncolytic virus drug for treating malignant glioma.
Teserpaturev is a cancer treatment virus drug co-developed with Professor Tomoki Todo of the Institute of Medical Science at the University of Tokyo. Its manufacturing and marketing approval was granted based on a Phase 2 clinical trial led by Professor Todo in patients with malignant glioma.
Dosing Schedule for Adult Malignant Glioma Patients
- 1st and 2nd administrations: Treatment cycle of 5–14 days
- 3rd through 6th administrations: Treatment cycle of every 4 weeks
Daiichi Sankyo stated: "We hope this product will provide a new treatment option for malignant glioma patients with unmet medical needs, thereby contributing to patients' well-being."
In June 2021, teserpaturev received conditional and time-limited manufacturing and marketing authorization as a regenerative medicine product for treating malignant glioma. It is currently only available at clinical trial institutions.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202111/20211101_J.pdf
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4